Retractable Technologies (RVP) risk factors, FY2025 10-K

Retractable Technologies's FY2025 10-K, filed Mar 27, 2026, lists 16 risk factors. Against the prior year's 15: 1 new, 7 substantially reworded.

Open RVP in Gloom →
Retractable Technologies' chart, financials and news, free in your browser.Open RVP in Gloom →
Risk factors listed
160 groups
New this year
1vs 15 last year
Dropped
0since the prior 10-K
Substantially reworded
7of those kept
Section length
3k wordsItem 1A

What the changes say

  • Geopolitical conflict is newly identified as a threat to component and finished-goods availability and cash flows.
  • GLP-1 therapies and CDC vaccination recommendations are identified as potential drivers of lower needle demand.
  • Tariff exposure remains material while domestic production expansion faces execution and cost-competitiveness uncertainty.
  • The company adds quality-control assurances and says recalls historically caused no material impact.

What changed since the prior 10-K

New

  • New

    Geopolitical conflicts, including ongoing tensions in the Middle East, could disrupt our supply chain and limit the timely availability of components or finished goods, which could materially and adversely affect our results of operations and cash flows

    Middle East tensions and other geopolitical conflicts could disrupt components, finished-goods availability, supply chains, results, and cash flows.

Reworded

  • 73% rewritten

    We Face Inherent Product Liability Risks

    The company removes the specific 2024 EasyPoint recall disclosure and adds no material historical recall impact plus stringent quality controls.

  • 70% rewritten

    We Are Concerned that Our Stock Price is Not Correlated with Value

    Year-end market capitalization rose from $20.7 million to $23.1 million, while stockholders’ equity fell from $87.2 million to $74.4 million.

  • 62% rewritten

    Supply Chain Disruptions Could Negatively Impact our Profitability

    No substantive change; reliance on Chinese manufacturers and the expanding domestic supply chain remains the stated disruption risk.

  • 61% rewritten

    We Are Vulnerable to New Technologies

    The company adds GLP-1 treatments, other long-acting therapies, and changing clinical practices as possible causes of lower injectable-device demand.

  • 46% rewritten

    Vaccine Hesitancy Could Impact Demand

    The company adds U.S. public-health policy and CDC vaccination recommendations as potential causes of reduced vaccine-administration demand.

  • 30% rewritten

    We are subject to risks associated with foreign trade policy. In 2025, we used Chinese manufacturers to produce 62.6% of our products

    The company removes the expected material increase in imported-goods costs and adds uncertainty about successfully expanding cost-competitive domestic production.

    Was: We are subject to risks associated with foreign trade policy. In 2024, we used Chinese manufacturers to produce 83.9% of our products

  • 21% rewritten

    Our Competitors Have Greater Resources

    No substantive change; larger competitors still have greater resources, distribution, market influence, and product-development capabilities.

All 16 risk factors

Headings as the filing states them, in filing order.

Other

  1. 01We are subject to risks associated with foreign trade policy. In 2025, we used Chinese manufacturers to produce 62.6% of our products30% rewritten
  2. 02We Are Concerned that Our Stock Price is Not Correlated with Value70% rewritten
  3. 03Our Customers Have Excess Product In Inventory and We Cannot Predict When It Will Be Depleted
  4. 04We Are Challenged by Uncertainties in Obtaining and Enforcing Intellectual Property Rights
  5. 05We Are Vulnerable to New Technologies61% rewritten
  6. 06Our Competitors Have Greater Resources21% rewritten
  7. 07We Are Controlled by One Shareholder
  8. 08Defensive Measures to Deter Hostile Takeovers
  9. 09Supply Chain Disruptions Could Negatively Impact our Profitability62% rewritten
  10. 10Geopolitical conflicts, including ongoing tensions in the Middle East, could disrupt our supply chain and limit the timely availability of components or finished goods, which could materially and adversely affect our results of operations and cash flowsNew
  11. 11Vaccine Hesitancy Could Impact Demand46% rewritten
  12. 12We Face Inherent Product Liability Risks73% rewritten
  13. 13Our Business May Be Affected by Changes in the Health Care Regulatory Environment
  14. 14We May Experience Losses in Our Investment Account
  15. 15Health Crises Could Have an Adverse Effect on Our Business
  16. 16Illegal Distribution and Sale by Third Parties of Counterfeit Versions of Our Products Could Have a Negative Impact

Other Retractable Technologies 10-Ks

  • FY2024 10-K risk factors
    15 risks

    Foreign manufacturing reliance and new tariffs heavily threaten operations and profitability. Excess pandemic inventory depresses current domestic product demand. High concentration of voting power rests with CEO Thomas J. Shaw.

    Filed Mar 28, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.